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The development of clinical practice guidelines for the
treatment of anemia in chronic kidney disease has been
instrumental in identifying and reducing variations in the
use of erythropoiesis-stimulating agents and iron
replacement. Challenges to the effectiveness and safety of
recommendations made in these guidelines were magnified
when recent clinical trials showed no benefit or harm with
respect to cardiovascular outcomes in subjects randomized
to higher target hemoglobin levels. To address these
concerns, Kidney Disease: Improving Global Outcomes
(KDIGO) convened an international conference to examine
the problems and shortcomings of existing anemia
guidelines, which are a prime example of duplication of
efforts to derive recommendations from a limited evidence
base. The meeting was attended by representatives of the
major guideline developing organizations, who agreed to
avoid future duplicative efforts and to save resources in
generating a common evidence report, whose
recommendations could then be prioritized and
implemented locally. This is a report to the international
nephrology community of the recommendations for and
timeline of the next anemia guidelines. It has been
reviewed by the conference participants and approved
as a position statement by the KDIGO Board of Directors.
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The introduction of erythropoietin into clinical practice in
1989 has been associated with controversies and concerns,
which remain after almost two decades of investigation
and practical experience. When to start, how to use, what
targets to achieve, and what outcomes to assess are but
some of the questions that persist in the management of
anemia in dialysis patients. The debate expanded when
the use of erythropoietin was extended into the treatment
of anemia in earlier stages of chronic kidney disease
(CKD), before the need for dialysis. The publication of
clinical practice guidelines on the management of anemia
in CKD by several organizations has been instrumental in
reducing the wide variations in practice that followed the
initial use of erythropoietin. The gaps in knowledge
identified in these guidelines have provided a basis for much
of the research that has been published on the subject since
that time.
An upper limit of the targeted hemoglobin level was a
component of the initial guidelines1 because of the Normal
Hematocrit Cardiac Trial published in 1998,2 which sug-
gested that attempts to normalize hematocrit in hemodialysis
patients was associated with harm. The upper limit for
targeted hemoglobin was liberalized in the course of updating
the original guidelines because of observational studies
showing a reduction in hospitalization, morbidity, and
mortality at higher achieved levels of hemoglobin.3–5 Never-
theless, concerns remained because of the limited available
data on the effectiveness, efficacy, and safety of the
recommended targets, especially when complete correction
of anemia did not lead to an associated improvement in the
left ventricular mass.6 These concerns were magnified when
two large clinical trials in patients with CKD stages 3 and 4
(CHOIR and CREATE) were published in November 2006
showing no benefit in one (CREATE) and harm in the other
http://www.kidney-international.org m e e t i n g r e p o r t
& 2008 International Society of Nephrology
Received 21 February 2008; revised 17 April 2008; accepted 22 April
2008; published online 2 July 2008
Correspondence: Tom Manley, National Kidney Foundation, 30 E, 33rd
Street, New York, New York 10016, USA. E-mail: Tomm@Kidney.Org
Kidney International (2008) 74, 1237–1240 1237
(CHOIR) with respect to cardiovascular outcomes in subjects
randomized to a higher target hemoglobin level.7,8 The
subsequent debate extended beyond the medical literature,
entailed regulatory agencies, and challenged the existing
guidelines that were, in fact, the catalysts that prompted some
of the very clinical trials that initiated the controversy.9
To address these issues, Kidney Disease Outcomes Quality
Initiative (KDOQI), which had released its updated anemia
guidelines in 2006 prior to the new data being published,
reconvened a workgroup to review these and other newer
studies. After thorough assessment of all the available
evidence, including the recently published trials, KDOQI
published revised recommendations for the target hemo-
globin level in CKD patients in September 2007.10
At the same time, KDIGO convened a meeting in October
2007 to review anemia management in CKD patients and to
develop recommendations for future guidelines in this field.
This report presents the deliberations and recommendations
of the meeting. It has been reviewed by the conference
participants and adopted as a position statement by the
KDIGO Board of Directors.
CONFERENCE PROCEEDINGS
The agenda, scope of work, papers, and documents distributed
at the meeting, and other pertinent material mentioned in this
report are posted on the KDIGO website (http://www.
kdigo.org). The scope of work acknowledged the importance
of correcting anemia and emphasized the importance for the
international nephrology community to come together to
evaluate emerging safety and efficacy concerns in anemia
correction, identify gaps in knowledge, and adopt a common
approach to future anemia guidelines that would avoid
duplication of efforts in deriving recommendations from a
limited evidence base. In preparation for the meeting, the
conference co-chairs (Francesco Locatelli and Allen Nissenson)
worked together with the KDIGO co-chairs (Norbert Lameire,
Kai-Uwe Eckardt, and Garabed Eknoyan) to define the issues
to be addressed; to evaluate on-going clinical trials in the
treatment of anemia in CKD, cancer, and cardiovascular
disease; and to compile a participant list. Invited participants
included the leadership of five principal guideline develop-
ment organizations (Caring for Australians with Renal
Impairment (CARI), Canadian Society of Nephrology
(CSN), European Best Practice Guidelines (EBPG), KDOQI,
and United Kingdom Renal Association (UK-RA)); their
experts in the development and implementation of guidelines,
methodologists, specialists in quality-of-life (QOL) measure-
ment in CKD, and other investigators in the field.
The meeting started with a plenary session during which
the presenters provided a comparison of the methodology
and recommended hemoglobin target levels of the five
principal guidelines published in English; the evidence base
of the recommendations of the KDOQI 2007 update; an
overview of the status of new erythropoiesis-stimulating
agents (ESA) and iron supplements; the design and timeline
of the ongoing Trial to Reduce Cardiovascular Events With
Aranesp Therapy (TREAT) study,11 the merits, and limita-
tions of QOL studies in CKD; and the need for the
coordination of future guidelines on anemia in CKD. The
participants then met in two breakout groups to address the
topics covered, and a number of specific questions were
designed to consider the existing knowledge, how it can be
used, and the direction of future research. The recommenda-
tions of each of the breakout groups were then presented by
their respective leaders and rapporteurs (Rowan Walker,
David Wheeler, Brendan Barrett, Francesco Locatelli, and
Allen Nissenson) to the entire group for discussion and
refinement. What follows is a summary of the deliberations
and specific recommendation made.
FRAMING THE ISSUES
There was a widespread agreement on the following issues
and gaps in knowledge that deserve to be examined in future
studies:
Anemia
(1) The current evidence, based on mortality data, for
hemoglobin target levels intentionally aimed with ESA
treatment in CKD patients treated indicates that
K levels of 413 g per 100 ml can be associated with
harm,
K levels of 9.5–11.5 g per 100 ml are associated with
better outcomes compared with 413 g per 100 ml
K for levels between 11.5 and 13 g per 100 ml, there is
no evidence at this time for harm or benefit
compared with higher or lower levels.
(2) The relationship of the dose of ESA used and outcomes
has not been examined adequately. Associations between
the need for higher doses of ESA and poor outcomes
could be surrogates for underlying comorbidities or
toxicity. Outcome studies of ESAs have heretofore based
their interventional strategies on hemoglobin levels only,
wherein the levels of hemoglobin achieved is equated
with efficacy. There is a need to broaden the primary end
points of clinical trials. Studies examining a given dose of
ESA, as opposed to, or in combination with, that of an
achieved hemoglobin target, are needed to evaluate
resistance, nonresponsiveness, and ESA toxicity.
(3) The mechanisms of resistance to anemia correction
remain poorly defined. A consistent definition of ESA
resistance is crucial for future research. Proposed resis-
tance indices need evaluation and validation. Markers
that can predict nonresponsiveness should be explored.
(4) QOL studies published heretofore are of varying quality
and often inconclusive, but suggest some improvement
following the correction of anemia with ESAs. The
science of QOL assessment has evolved and more reliable
methods of determining patient-related outcomes and
functional status are now available. There is a need for
more robust randomized clinical trials where appropriate
QOL domains are the primary end points at different
levels of hemoglobin.
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(5) There is a considerable heterogeneity in the patient data
used in meta-analyses, which cover the spectrum of
patients with CKD. Differences in the outcomes of
anemia treatment between dialysis patients and those in
CKD stages 1–5 are not clear. The impact of comorbid-
ities and intercurrent illnesses on targets has not been
well examined. Individual patient data meta-analysis
should be performed using existing databases to further
explore potential sources of heterogeneity.
(6) In addition to the analysis of available databases,
randomized clinical trials should be performed to
enhance our understanding of the profile of high-risk
patients, exploring the impact of comorbidities, treat-
ment modalities, and intercurrent illnesses on outcomes
at different target hemoglobin levels.
(7) A better understanding of hemoglobin kinetics in the ESA
correction of anemia is required. Variations in hemoglobin
levels (hemoglobin cycling), what they mean, and their
clinical implications, if any, deserve further elucidation.
Iron supplementation
(1) The tools for measuring iron status are crude.
(2) Recommended iron levels are directed at optimizing ESA
use and target hemoglobin levels. The potential toxicity
of iron remains an issue that should be investigated and
elucidated.
(3) There is lack of information comparing the efficacy and
safety of various iron preparations, regimens, and routes
of administration.
Anemia guidelines
(1) Published guidelines largely ignore transfusion reduction
as a primary reason for ESA use.
(2) Guidelines need to provide clear descriptions not only of
what is known but also of the gaps in current knowledge.
(3) The evidence tables in published guideline documents
would benefit from explanatory notes interpreting the
data presented to general users of the guidelines.
(4) Guidelines should address whether recommended targets
need to be followed in individuals who are acutely ill or
have chronic inflammation.
(5) Guidelines should comment on the data generated from
studies in cancer and cardiac patients and their
implications for the use of ESAs in CKD patients.
(6) The KDOQI 2006 update and its subsequent 2007
modification are comprehensive documents, which
represent a good summary of the current evidence and
provide sound recommendations.
CONCLUSION AND RECOMMENDATIONS
In the closing plenary session, there was considerable
discussion on how the KDOQI guidelines could be used in
the context of other available guidelines. There was a general
agreement that there is insufficient new data to justify a
revision of these guidelines at the present time.12 On the
other hand, despite the international composition of the
KDOQI anemia guideline development workgroup, concern
was expressed about the challenge they present from a global
perspective, bearing in mind regional policies, resources, and
sensitivities. It was pointed out that there is a distinction
between the factual evidence report of guidelines and its
interpretation in the consensus-developed statement of
recommendations made. As with any other guidelines,
regional resources and policies vary resulting in different
levels of recommendation arising from the same scientific
evidence. The stated concerns notwithstanding, it was agreed
that there is a clear need to save resources and avoid
duplication in the next iteration of guidelines, which should
be developed as a cooperative global undertaking. Although
the level of comfort and acceptance of such a project needs to
be nurtured, any obstacles that exist to producing a common
global guideline can be overcome. It is recommended that
1. The next clinical practice guidelines on anemia in CKD,
including the new evidence review process, would be a
coordinated effort undertaken by KDIGO.
2. Based on anticipated results from key on-going studies, it
is reasonable to plan for a start-up date no earlier than
2009, with an anticipated completion date of 2011.
3. Adoption and implementation of the guidelines will
remain a regional decision based on the evidence tables
of the new KDIGO guidelines. Given the differences in
health-care systems and resource availability, the priori-
tization and strength of individual recommendations
made would have to be undertaken at the regional level,
wherever deemed necessary.
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